Bovela Injection for Cattle 50 Dose

Category: B

Select Option
Bovela Injection for Cattle 50 Dose - € 461.96
QTY:
Bovela Injection for Cattle 5 Dose - € 53.23
QTY:
Bovela Injection for Cattle 25 Dose - € 251.06
QTY:

Total Price: €0.00


Vat Rate: 20%

Prescription Required



For active immunisation of cattle from 3 months of age to reduce hyperthermia and to minimise the reduction of leukocyte count caused by bovine viral diarrhoea virus (BVDV-1 and BVDV-2), and to reduce virus shedding and viraemia caused by BVDV-2. For active immunisation of cattle against BVDV-1 and BVDV-2, to prevent the birth of persistently infected calves caused by transplacental infection. Onset of immunity: 3 weeks after immunisation. Duration of immunity: 1 year after immunisation.

Royal Mail 2nd Class / Parcel Force 48

UK to UK :Normally arrives in 2-4 business days.

UK to Ireland :Normally arrives in 4-6 business days

UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going

 

Please note standered delivery is none trackable , none insured , no responsabily for lose or Damage

 

----------------------------------------------------------------------------------------------------------------

 

Royal Mail First Class / Parcel Force 24

UK to UK :Normally arrives in 1-2 business days.

UK to Ireland 3-4 business days

UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going

 

Please note :Trackable , Royal Mail insured up to £50.

 

--------------------------------------------------------------------------------------------------------

Parcel Force Express AM Guaranteed before Midday.

UK to UK only . UP to 5KG Max Weight

Arrives next day before 12 noon, requires a signature.

 

Parcel Forcel Terms & Conditions apply

 

Important: Parcel Force advise that there are some postcodes where an extended delivery time exists, and may affect the date of delivery or the service is not available.

 

You must be logged in to write review
Category POM-V
Temperature Refrigerated
MA/VM/EU No: EU/2/14/176/001-016
Species
  • cattle
VMD Link Product Information Database (defra.gov.uk)
NOAH Link https://www.noahcompendium.co.uk/?id=-447471
Dosage Dosage and administration Intramuscular use. Preparation of vaccine for use (reconstitution): Reconstitute the lyophilisate by adding the full content of the solvent at room temperature. Ensure that the lyophilisate is completely reconstituted before use. The reconstituted vaccine is transparent and colourless. Avoid multiple broaching. Primary vaccination: After reconstitution, administer one dose (2 ml) of the vaccine by intramuscular (IM) injection. It is recommended to vaccinate cattle at least 3 weeks before insemination/mating to provide foetal protection from the first day of conception. Animals which are vaccinated later than 3 weeks before gestation or during the early gestation may not be protected against foetal infection. This should be considered in case of herd vaccination. Recommended re-vaccination programme: Revaccination is recommended after 1 year. 12 months after primary vaccination most studied animals still had antibody titres at plateau while some animals had lower titres. Contra-indications, warnings, etc Do not use in cases of hypersensitivity to the active substances or to any of the excipients. Special precautions for each target species Vaccinate healthy animals only. To ensure the protection of animals introduced to the herd where BVDV is circulating, vaccination has to be completed 3 weeks before introduction. The cornerstone of bovine viral diarrhoea (BVD)-eradication is identification and culling of persistently infected animals. A definitive diagnosis of persistent infection can only be established upon re-testing in blood after an interval of at least 3 weeks. In some limited cases with newborn calves, positive ear notches for BVDV vaccine strain were reported by molecular diagnostic tests. Additional laboratory tests to differentiate vaccine strain virus from field strain are available upon request from the marketing authorization holder. The field studies to investigate the efficacy of the vaccine were done in herds where persistently infected animals had been removed. Special precautions for use in animals Longlasting viremia has been observed after vaccination, in particular in pregnant seronegative heifers (10 days in a study). This may result in transplacental transmission on the vaccine virus, but no adverse effects on foetus or pregnancy were observed in studies. Shedding of the vaccine virus by body fluids can not be excluded. The vaccine strains are able to infect sheep and swine when administered intranasally, but no adverse reactions or spreading to in-contact animals has been demonstrated. The vaccine has not been tested in breeding bulls and should therefore not be used in breeding bulls. Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. Adverse reactions (frequency and seriousness) An increase in body temperature within the physiological range is common within 4 hours of vaccination and spontaneously resolves within 24 hours (clinical studies). Mild swellings or nodules up to 3 cm diameter were observed at the injection site and disappeared within 4 days post vaccination (clinical studies). Hypersensitivity reactions, including anaphylactic-type reactions, have been reported very rarely (post-marketing safety experience). The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). Pregnancy and Lactation It is recommended to vaccinate before pregnancy to ensure protection against persistent infection of the foetus. While persistent infection of the foetus caused by the vaccine was not observed, transmission of vaccine virus to the foetus may occur. Therefore, use during pregnancy should only be on a case-by-case basis decided by the responsible veterinarian, taking into consideration e.g. the BVD immunological status of the animal, the time-span between vaccination and mating/insemination, the stage of pregnancy and the risk of infection. Can be used during lactation. Studies have shown that vaccine virus may be excreted in milk up to 23 days after vaccination at low amounts (~ 10 TCID50/ml), although when such milk was fed to calves, no seroconversion occurred in those calves. Interactions No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. Overdose Mild swellings or nodules up to 3 cm diameter were observed at the injection site after administration of a 10-fold overdose and disappeared within 4 days post vaccination. Furthermore, an increase of the rectal body temperature was common within 4 hours following administration and spontaneously resolves within 24 hours.
Withdrawals